Mydecine Innovations Group Inc. (OTCMKTS:MYCOF – Get Free Report) was down 45% on Thursday . The company traded as low as $1.10 and last traded at $1.10. Approximately 4,678 shares changed hands during mid-day trading, an increase of 31% from the average daily volume of 3,575 shares. The stock had previously closed at $2.00.
Mydecine Innovations Group Stock Performance
The firm has a fifty day moving average of $1.53 and a two-hundred day moving average of $0.88.
Mydecine Innovations Group Company Profile
Mydecine Innovations Group (OTCMKTS:MYCOF) is a clinical?stage biotechnology company dedicated to the research, development and commercialization of novel therapeutics derived from psychedelic and plant-based compounds. The company’s primary focus lies in advancing a pipeline of next?generation product candidates targeting mental health disorders, addiction and other neurological conditions. Mydecine holds a portfolio of intellectual property that encompasses proprietary chemical entities, drug delivery systems and manufacturing processes for molecules such as 5-MeO-DMT analogs, ibogaine-derived compounds and psilocybin formulations.
Headquartered in Denver, Colorado, with additional research and manufacturing facilities in Vancouver, Canada, Mydecine operates a vertically integrated business model.
Further Reading
- Five stocks we like better than Mydecine Innovations Group
- Starbucks Builds Sovereign AI to Cut $400 Million in Software Costs
- Power Struggle: Wolfspeed Sues Navitas Over AI Chips
- Why WD-40 Is Proving Great Businesses Never Go Out of Style
- Pushing the Edge: Super Micro Computer Reboots the AI Landscape
Receive News & Ratings for Mydecine Innovations Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mydecine Innovations Group and related companies with MarketBeat.com's FREE daily email newsletter.
